On the public citation graph

Sunitinib: the antiangiogenic effects and beyond

0 signed · 198 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 85 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-21): 10.1186/1476-4598-12-17 (notice 2021-06-11).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.295.21.2516openalex-snapshot

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

inferredcites →https://doi.org/10.1002/cncr.25583openalex-snapshot

Sunitinib rechallenge in metastatic renal cell carcinoma patients

inferredcites →https://doi.org/10.1002/cncr.29044openalex-snapshot

The RET oncogene in papillary thyroid carcinoma

inferredcites →https://doi.org/10.1002/cncr.29220openalex-snapshot

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

inferredcites →https://doi.org/10.1007/s00262-015-1735-zopenalex-snapshot

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

inferredcites →https://doi.org/10.1007/s10456-004-3149-yopenalex-snapshot

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

inferredcites →https://doi.org/10.1007/s10637-013-0032-yopenalex-snapshot

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

inferredcites →https://doi.org/10.1007/s11060-015-1720-6openalex-snapshot

Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes

inferredcites →https://doi.org/10.1007/s11523-013-0280-yopenalex-snapshot

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases

inferredcites →https://doi.org/10.1016/bs.acr.2015.04.002openalex-snapshot

Myeloid-Derived Suppressor Cells

inferredcites →https://doi.org/10.1016/j.ccr.2004.08.031openalex-snapshot

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

inferredcites →https://doi.org/10.1016/j.ccr.2007.12.004openalex-snapshot

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

inferredcites →https://doi.org/10.1016/j.ccr.2009.01.021openalex-snapshot

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

inferredcites →https://doi.org/10.1016/j.ccr.2009.01.027openalex-snapshot

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

inferredcites →https://doi.org/10.1016/j.critrevonc.2010.02.004openalex-snapshot

Targeting immune suppressing myeloid-derived suppressor cells in oncology

inferredcites →https://doi.org/10.1016/j.critrevonc.2015.01.006openalex-snapshot

Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): A systematic review of the literature

inferredcites →https://doi.org/10.1016/j.ejca.2009.02.011openalex-snapshot

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

inferredcites →https://doi.org/10.1016/j.ejca.2014.01.025openalex-snapshot

A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

inferredcites →https://doi.org/10.1016/j.juro.2013.08.090openalex-snapshot

Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules

inferredcites →https://doi.org/10.1016/j.neo.2015.11.001openalex-snapshot

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma

inferredcites →https://doi.org/10.1016/j.smim.2016.01.002openalex-snapshot

Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment

inferredcites →https://doi.org/10.1016/j.urolonc.2013.10.004openalex-snapshot

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature

inferredcites →https://doi.org/10.1016/j.urolonc.2015.03.003openalex-snapshot

Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature

inferredcites →https://doi.org/10.1016/s0140-6736(06)69446-4openalex-snapshot

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

inferredcites →https://doi.org/10.1016/s1040-1741(08)70351-8openalex-snapshot

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

inferredcites →https://doi.org/10.1021/jm0204183openalex-snapshot

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3 Z )-ylidenemethyl]-2,4- dimethyl-1 H -pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

inferredcites →https://doi.org/10.1021/jm980718dopenalex-snapshot

Molecular Modeling and Synthesis of Inhibitors of Herpes Simplex Virus Type 1 Uracil-DNA Glycosylase

inferredcites →https://doi.org/10.1038/bjc.2013.832openalex-snapshot

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

inferredcites →https://doi.org/10.1038/nrclinonc.2015.210openalex-snapshot

Molecular therapy for acute myeloid leukaemia

inferredcites →https://doi.org/10.1038/onc.2015.343openalex-snapshot

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

inferredcites →https://doi.org/10.1038/sj.bjc.6605552openalex-snapshot

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

inferredcites →https://doi.org/10.1056/nejmoa065044openalex-snapshot

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

inferredcites →https://doi.org/10.1056/nejmoa1003825openalex-snapshot

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

inferredcites →https://doi.org/10.1073/pnas.92.14.6254openalex-snapshot

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

inferredcites →https://doi.org/10.1084/jem.181.1.435openalex-snapshot

Inhibition of tumor growth by elimination of granulocytes.

inferredcites →https://doi.org/10.1093/annonc/mdq342openalex-snapshot

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

inferredcites →https://doi.org/10.1093/annonc/mdv315openalex-snapshot

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

inferredcites →https://doi.org/10.1093/annonc/mdv357openalex-snapshot

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

inferredcites →https://doi.org/10.1097/01.cji.0000191065.34501.e3openalex-snapshot

Tumor Associated CD8+ T-Cell Tolerance Induced by Bone Marrow Derived Immature Myeloid Cells

inferredcites →https://doi.org/10.1111/ajco.12465openalex-snapshot

Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma

inferredcites →https://doi.org/10.1111/bju.12232openalex-snapshot

Copy number aberrations using multicolour fluorescence in situ hybridization ( FISH ) for prognostication in non‐muscle‐invasive bladder cancer ( NIMBC )

inferredcites →https://doi.org/10.1111/j.1349-7006.2006.00263.xopenalex-snapshot

Effect of SU11248 on gastrointestinal stromal tumor‐T1 cells: Enhancement of growth inhibition via inhibition of 3‐kinase/Akt/mammalian target of rapamycin signaling

inferredcites →https://doi.org/10.1111/j.1365-2133.2009.09290.xopenalex-snapshot

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

inferredcites →https://doi.org/10.1158/0008-5472.can-08-4709openalex-snapshot

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2655openalex-snapshot

Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma

inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-2328openalex-snapshot

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1332openalex-snapshot

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-0190openalex-snapshot

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-0482openalex-snapshot

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-0994openalex-snapshot

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-1667openalex-snapshot

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-3005openalex-snapshot

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-0411openalex-snapshot

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-2742openalex-snapshot

Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy

inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-1377openalex-snapshot

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer

inferredcites →https://doi.org/10.1158/2326-6066.cir-14-0076openalex-snapshot

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

inferredcites →https://doi.org/10.1161/01.atv.17.11.2793openalex-snapshot

Vascular Endothelial Growth Factor/Vascular Permeability Factor Produces Nitric Oxide–Dependent Hypotension

inferredcites →https://doi.org/10.1172/jci41936openalex-snapshot

Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation

inferredcites →https://doi.org/10.1172/jci80005openalex-snapshot

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

inferredcites →https://doi.org/10.1186/1471-2407-12-107openalex-snapshot

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

inferredcites →https://doi.org/10.1186/1476-4598-12-17openalex-snapshot

RETRACTED ARTICLE: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

inferredcites →https://doi.org/10.1200/jco.2005.02.2574openalex-snapshot

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

inferredcites →https://doi.org/10.1200/jco.2007.15.7461openalex-snapshot

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

inferredcites →https://doi.org/10.1200/jco.2007.15.9020openalex-snapshot

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

inferredcites →https://doi.org/10.1200/jco.2008.17.2742openalex-snapshot

Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor

inferredcites →https://doi.org/10.1200/jco.2008.20.1293openalex-snapshot

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

inferredcites →https://doi.org/10.1200/jco.2008.20.3034openalex-snapshot

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

inferredcites →https://doi.org/10.1200/jco.2009.26.9696openalex-snapshot

A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors

inferredcites →https://doi.org/10.1200/jco.2011.36.4133openalex-snapshot

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

inferredcites →https://doi.org/10.1200/jco.2014.57.3105openalex-snapshot

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

inferredcites →https://doi.org/10.1200/jco.22.02623openalex-snapshot

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

inferredcites →https://doi.org/10.1371/journal.pone.0130980openalex-snapshot

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

inferredcites →https://doi.org/10.1517/14656566.8.14.2359openalex-snapshot

Sunitinib

inferredcites →https://doi.org/10.1530/eje-14-0682openalex-snapshot

Sunitinib achieved fast and sustained control of VIPoma symptoms

inferredcites →https://doi.org/10.1530/eje-15-0930openalex-snapshot

Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer

inferredcites →https://doi.org/10.1586/era.13.45openalex-snapshot

Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma

inferredcites →https://doi.org/10.1634/theoncologist.2012-0044openalex-snapshot

FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

inferredcites →https://doi.org/10.2147/ott.s49430openalex-snapshot

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

inferredcites →https://doi.org/10.2217/fon.13.128openalex-snapshot

Cabozantinib (XL184) for the Treatment of Locally Advanced or Metastatic Progressive Medullary Thyroid Cancer

inferredcites →https://doi.org/10.4049/jimmunol.0902661openalex-snapshot

Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells

inferredcites →https://doi.org/10.4049/jimmunol.162.10.5728openalex-snapshot

Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation

inferredcites →https://doi.org/10.4049/jimmunol.175.7.4583openalex-snapshot

Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells

inferredcites →https://doi.org/10.4049/jimmunol.181.5.3291openalex-snapshot

Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes

inferredcites →https://doi.org/10.4143/crt.2009.41.2.67openalex-snapshot

Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea

inferredcites →https://doi.org/10.4161/2162402x.2014.989764openalex-snapshot

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.3897/pharmacia.72.e141634zenodo-depositor-declared

Inhibition of MERS-CoV papain-like protease by sunitinib: In vitro and in silico investigations

inferred← citeshttps://doi.org/10.1002/ardp.202000022openalex-snapshot

Structure–activity relationship studies of indolin‐2‐one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents

inferred← citeshttps://doi.org/10.1002/bcp.70565openalex-snapshot

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

inferred← citeshttps://doi.org/10.1002/bkcs.70178openalex-snapshot

A sequential Ugi‐click reactions approach for generation of novel hybrid amides/triazole‐sulfonamide as VEGFR ‐2 inhibitors targeting NSCLC and triple‐negative breast cancer

inferred← citeshttps://doi.org/10.1002/cmdc.202500634openalex-snapshot

Design, Synthesis, and Cytotoxicity Evaluation of Styryl‐Spirooxindole Carboxamides as Potential Tubulin and VEGFR‐2 Dual Inhibitors

inferred← citeshttps://doi.org/10.1002/ddr.22058openalex-snapshot

Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway

inferred← citeshttps://doi.org/10.1002/jex2.52openalex-snapshot

ELTD1 is present in extracellular vesicles derived from endothelial cells as a cleaved extracellular domain which induces in vivo angiogenesis

inferred← citeshttps://doi.org/10.1002/jum.70353openalex-snapshot

Ultra‐High Frequency Ultrasound Imaging and Quantification of Microvascular Flow in Xenograft Renal Cell Carcinoma in an Avian Chorioallantoic Membrane Model

inferred← citeshttps://doi.org/10.1002/onco.13842openalex-snapshot

Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial

inferred← citeshttps://doi.org/10.1002/slct.73249openalex-snapshot

Six‐Membered Heterocycles as VEGFR‐2 Kinase Inhibitors: A Structural and Therapeutic Review

inferred← citeshttps://doi.org/10.1002/tcr.202200152openalex-snapshot

Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy

inferred← citeshttps://doi.org/10.1002/vro2.27openalex-snapshot

Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009–2019)

inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_274-1openalex-snapshot

Angiogenesis Inhibitors in the Treatment of Cancer

inferred← citeshttps://doi.org/10.1007/978-3-031-11284-3_2openalex-snapshot

Current Anti-angiogenic Therapies and Their Limitations

inferred← citeshttps://doi.org/10.1007/978-3-032-00771-1_274openalex-snapshot

Angiogenesis Inhibitors in the Treatment of Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-93530-0_1openalex-snapshot

Role and Therapeutic Implications of MDSCs in Sarcomas

inferred← citeshttps://doi.org/10.1007/978-981-15-7586-0_9openalex-snapshot

Angiogenesis: A Therapeutic Target for Cancer

inferred← citeshttps://doi.org/10.1007/s00018-019-03351-7openalex-snapshot

Tumor angiogenesis: causes, consequences, challenges and opportunities

inferred← citeshttps://doi.org/10.1007/s00775-020-01770-7openalex-snapshot

New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities

inferred← citeshttps://doi.org/10.1007/s10238-024-01507-9openalex-snapshot

The prognostic implications and oncogenic role of NSUN5 in clear cell renal cell carcinoma

inferred← citeshttps://doi.org/10.1007/s10585-021-10098-8openalex-snapshot

Myeloid derived suppressor cells and the release of micro-metastases from dormancy

inferred← citeshttps://doi.org/10.1007/s10989-016-9567-zopenalex-snapshot

A PlGF-1 Derived Peptide Inhibits Angiogenesis via HIF-1β/VEGF Pathway

inferred← citeshttps://doi.org/10.1007/s11095-026-04124-1openalex-snapshot

High-Dose Sunitinib Accelerates Triple-Negative Breast Cancer Metastasis by Modulating an Immunosuppressive Microenvironment: A Preclinical 4T1 Model Study

inferred← citeshttps://doi.org/10.1007/s11696-026-04729-1openalex-snapshot

Heterocyclic anticancer agents targeting VEGFR-2: synthetic approaches to key scaffolds

inferred← citeshttps://doi.org/10.1007/s11696-026-05373-5openalex-snapshot

Pyrroles and fused pyrroles: synthesis strategies and medicinal values

inferred← citeshttps://doi.org/10.1007/s12265-023-10431-4openalex-snapshot

The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity

inferred← citeshttps://doi.org/10.1007/s12668-026-02762-8openalex-snapshot

Development and In Vivo Evaluation of Sunitinib-loaded Cubosomes for Enhanced Oral Bioavailability

inferred← citeshttps://doi.org/10.1016/b978-0-12-818549-0.00018-2openalex-snapshot

Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors

inferred← citeshttps://doi.org/10.1016/b978-0-323-91215-0.00010-8openalex-snapshot

Photodynamic and photothermal therapy using PLGA nanoparticles

inferred← citeshttps://doi.org/10.1016/j.abb.2024.109986openalex-snapshot

Oleuropein attenuates the nephrotoxic effect of sunitinib in rats: Unraveling the potential role of SIRT6/Notch-1/NLRP-3/IL-1β axis

inferred← citeshttps://doi.org/10.1016/j.arr.2024.102287openalex-snapshot

Advances on Senescence-associated secretory phenotype regulated by circular RNAs in tumors

inferred← citeshttps://doi.org/10.1016/j.bcp.2025.116875openalex-snapshot

E3 ubiquitin ligases and their therapeutic potential in disease Management

inferred← citeshttps://doi.org/10.1016/j.bea.2024.100127openalex-snapshot

The advantages of microneedle patches compared to conventional needle-based drug delivery and biopsy devices in medicine

inferred← citeshttps://doi.org/10.1016/j.bioorg.2022.105622openalex-snapshot

New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies

inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.108957openalex-snapshot

Affinity-guided discovery of dimeric sesquiterpenes from Xylopia vielana as potent VEGFR-2 inhibitors with anti-angiogenic activity

inferred← citeshttps://doi.org/10.1016/j.canlet.2018.12.021openalex-snapshot

Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma

inferred← citeshttps://doi.org/10.1016/j.cellimm.2021.104312openalex-snapshot

Tumor-related stress regulates functional plasticity of MDSCs

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.03.007openalex-snapshot

Risk of fatal adverse events in cancer patients treated with sunitinib

inferred← citeshttps://doi.org/10.1016/j.ctarc.2025.101019openalex-snapshot

Harnessing nanotechnology for efficient delivery of indole-based drugs in cancer treatment

inferred← citeshttps://doi.org/10.1016/j.drudis.2021.07.008openalex-snapshot

G-protein-coupled receptors as therapeutic targets for glioblastoma

inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174021openalex-snapshot

Angiopoietin inhibitors: A review on targeting tumor angiogenesis

inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174512openalex-snapshot

Strategies for active tumor targeting-an update

inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178094openalex-snapshot

Drug-induced gingival diseases: insights from the FDA Adverse Event Reporting System (FAERS) database analysis

inferred← citeshttps://doi.org/10.1016/j.ijpharm.2022.121805openalex-snapshot

Intelligent porphyrin nano-delivery system for photostimulated and targeted inhibition of angiogenesis

inferred← citeshttps://doi.org/10.1016/j.jff.2023.105845openalex-snapshot

Flavonoids as receptor tyrosine kinase inhibitors in lung cancer

inferred← citeshttps://doi.org/10.1016/j.jpba.2019.112949openalex-snapshot

A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine

inferred← citeshttps://doi.org/10.1016/j.molliq.2024.126777openalex-snapshot

Synthesis of Semaxanib-like 3-alkylideneoxindoles and their binding investigation with ctDNA by multiple methods

inferred← citeshttps://doi.org/10.1016/j.nano.2019.02.015openalex-snapshot

Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools

inferred← citeshttps://doi.org/10.1016/j.taap.2023.116754openalex-snapshot

Intranasal delivery of sunitinib: A new therapeutic approach for targeting angiogenesis of glioblastoma

inferred← citeshttps://doi.org/10.1016/j.taap.2025.117423openalex-snapshot

Activation of Sig-1R by afobazole attenuates Tollip/HMGB1-mediaded CCN2 autophagic degradation and NETs formation in sunitinib-induced cardiotoxicity in mice: Involvement of IRE 1α/ASK1/JNK/ AP-1 trajectory

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c03554openalex-snapshot

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST

inferred← citeshttps://doi.org/10.1038/s41416-019-0558-7openalex-snapshot

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

inferred← citeshttps://doi.org/10.1038/s41598-024-70220-0openalex-snapshot

Hedgehog components are overexpressed in a series of liver cancer cases

inferred← citeshttps://doi.org/10.1039/d2bm01996eopenalex-snapshot

Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery

inferred← citeshttps://doi.org/10.1039/d3md00157aopenalex-snapshot

Design, synthesis, and biological evaluation of indole-modified tamoxifen relatives as potent anticancer agents

inferred← citeshttps://doi.org/10.1039/d3md00476gopenalex-snapshot

Novel pyrazolo[3,4- d ]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity

inferred← citeshttps://doi.org/10.1039/d3nr04806copenalex-snapshot

Engineered nanomicelles targeting proliferation and angiogenesis inhibit tumour progression by impairing the synthesis of ceramide-1-phosphate

inferred← citeshttps://doi.org/10.1039/d4ra05244gopenalex-snapshot

Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents

inferred← citeshttps://doi.org/10.1039/d6ra06419aopenalex-snapshot

Trends towards multidrug-resistant bacteria: heterocyclic compounds containing antimicrobial agents: review

inferred← citeshttps://doi.org/10.1067/j.cpradiol.2020.11.006openalex-snapshot

Imaging Spectrum of Infections in the Setting of Immunotherapy and Molecular Targeted Therapy

inferred← citeshttps://doi.org/10.1093/emph/eoad042openalex-snapshot

Spatial simulation of autologous cell defection for cancer treatment

inferred← citeshttps://doi.org/10.1093/noajnl/vdab133openalex-snapshot

Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?

inferred← citeshttps://doi.org/10.1093/toxsci/kfaf036openalex-snapshot

A workflow for human health hazard evaluation using transcriptomic data and Key Characteristics-based gene sets

inferred← citeshttps://doi.org/10.1096/fj.202000264openalex-snapshot

Porcine arterial ECM hydrogel: Designing an in vitro angiogenesis model for long‐term high‐throughput research

inferred← citeshttps://doi.org/10.1097/med.0000000000000330openalex-snapshot

Malignant pheochromocytoma–paraganglioma: pathogenesis, TNM staging, and current clinical trials

inferred← citeshttps://doi.org/10.1149/1945-7111/ae33faopenalex-snapshot

Electrochemical DNA Biosensor Based on Pt 2+ -Doped ZnCo 2 O 4 for Sensitive Detection of the Anti-Cancer Drug Sunitinib

inferred← citeshttps://doi.org/10.1161/hypertensionaha.122.17947openalex-snapshot

Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation

inferred← citeshttps://doi.org/10.1177/15330338241273239openalex-snapshot

Regulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis

inferred← citeshttps://doi.org/10.1186/s12964-024-01607-9openalex-snapshot

Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents

inferred← citeshttps://doi.org/10.1200/jco.22.00294openalex-snapshot

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

inferred← citeshttps://doi.org/10.1200/po.23.00513openalex-snapshot

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

inferred← citeshttps://doi.org/10.1530/ec-19-0192openalex-snapshot

EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?

inferred← citeshttps://doi.org/10.21037/gist-21-19openalex-snapshot

High proportion of wild-type gastrointestinal stromal tumor in a cohort of Chilean patients screened by KIT and PDGFRA exome profiling

inferred← citeshttps://doi.org/10.21203/rs.3.rs-5696509/v1openalex-snapshot

Efficacy and safety of atezolizumab plus bevacizumab versus sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.2147/jir.s353489openalex-snapshot

Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review

inferred← citeshttps://doi.org/10.2174/011871529x401261251128055509openalex-snapshot

Targeting Neuropeptide Y: Novel Approaches to the Treatment of Cardiovascular and Haematological Disorders

inferred← citeshttps://doi.org/10.2174/0122103031427846251203091456openalex-snapshot

Biopolymeric Nanocarriers of Tamarind Xyloglucan and Chitosan for Sunitinib Delivery: Formulation, Characterization, and Cytotoxicity Study

inferred← citeshttps://doi.org/10.2174/0929867324666171006165942openalex-snapshot

Sunitinib in the Treatment of Thyroid Cancer

inferred← citeshttps://doi.org/10.2174/1568009620666201229120332openalex-snapshot

Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.24198/idjp.v3i2.37368openalex-snapshot

Development of a quantitative method for sunitinib N-oxide

inferred← citeshttps://doi.org/10.32383/farmpol/141381openalex-snapshot

Indole derivatives with therapeutic properties

inferred← citeshttps://doi.org/10.32597/honors/230/openalex-snapshot

Synthesis of an Arylidene Pyrazolone and its Effects on Glioblastoma Cancer Cells

inferred← citeshttps://doi.org/10.3389/fendo.2018.00277openalex-snapshot

Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer

inferred← citeshttps://doi.org/10.3389/fimmu.2019.00771openalex-snapshot

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression

inferred← citeshttps://doi.org/10.3389/fonc.2023.1116016openalex-snapshot

Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment

inferred← citeshttps://doi.org/10.3389/fphar.2019.00508openalex-snapshot

Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae

inferred← citeshttps://doi.org/10.3389/fphar.2023.1157084openalex-snapshot

Preparation of a Sunitinib loaded microemulsion for ocular delivery and evaluation for the treatment of corneal neovascularization in vitro and in vivo

inferred← citeshttps://doi.org/10.3389/fphar.2023.1307860openalex-snapshot

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

inferred← citeshttps://doi.org/10.3389/fphar.2026.1783390openalex-snapshot

Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs

inferred← citeshttps://doi.org/10.3390/cancers11040531openalex-snapshot

Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

inferred← citeshttps://doi.org/10.3390/cancers11050611openalex-snapshot

Focus on Formononetin: Anticancer Potential and Molecular Targets

inferred← citeshttps://doi.org/10.3390/cancers16020350openalex-snapshot

Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice

inferred← citeshttps://doi.org/10.3390/ijms21020455openalex-snapshot

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

inferred← citeshttps://doi.org/10.3390/ijms22041631openalex-snapshot

Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine

inferred← citeshttps://doi.org/10.3390/ijms22041662openalex-snapshot

Paroxetine—Overview of the Molecular Mechanisms of Action

inferred← citeshttps://doi.org/10.3390/ijms22126467openalex-snapshot

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells

inferred← citeshttps://doi.org/10.3390/ijms22179441openalex-snapshot

Recent Advancements in the Medical Treatment of Diabetic Retinal Disease

inferred← citeshttps://doi.org/10.3390/ijms23074002openalex-snapshot

Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8

inferred← citeshttps://doi.org/10.3390/ijms241713317openalex-snapshot

Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors

inferred← citeshttps://doi.org/10.3390/ijms252312873openalex-snapshot

Unlocking the Potential of Pyrrole: Recent Advances in New Pyrrole-Containing Compounds with Antibacterial Potential

inferred← citeshttps://doi.org/10.3390/ijms27156590openalex-snapshot

Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood–Brain Barrier Dynamics and Combinatorial Translational Strategies

inferred← citeshttps://doi.org/10.3390/medicina55080414openalex-snapshot

Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology

inferred← citeshttps://doi.org/10.3390/molecules26040781openalex-snapshot

A 60% Edible Ethanolic Extract of Ulmus davidiana Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis

inferred← citeshttps://doi.org/10.3390/molecules27154757openalex-snapshot

Halogenated Flavonoid Derivatives Display Antiangiogenic Activity

inferred← citeshttps://doi.org/10.3390/ph16010097openalex-snapshot

Design, Synthesis, and Biological Evaluation of 2-Mercaptobenzoxazole Derivatives as Potential Multi-Kinase Inhibitors

inferred← citeshttps://doi.org/10.3390/ph19030379openalex-snapshot

KRDQN: An Interpretable Prediction Framework for Adverse Drug Reactions via Knowledge–Graph Reinforced Deep Q-Learning

inferred← citeshttps://doi.org/10.3390/pharmaceutics15071815openalex-snapshot

Indole Antitumor Agents in Nanotechnology Formulations: An Overview

inferred← citeshttps://doi.org/10.3390/scipharm88030030openalex-snapshot

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

inferred← citeshttps://doi.org/10.52711/0974-360x.2023.00328openalex-snapshot

Quality by Design based pareto charts responses Evaluation approach for a Validated Stability-indicating RP-HPLC assay Method for sunitinib and its process related impurities in Oral Dosage Forms

inferred← citeshttps://doi.org/10.5306/wjco.v15.i8.1092openalex-snapshot

Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis

inferred← citeshttps://doi.org/10.53853/encr.4.4.148openalex-snapshot

Nuevos conceptos en feocromocitoma y paraganglioma en el 2017

inferred← citeshttps://doi.org/10.5798/dicletip.1170070openalex-snapshot

Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic

inferred← citeshttps://doi.org/10.7759/cureus.70700openalex-snapshot

Hypoxia-Inducible Factor 1-Alpha (HIF-1α) and Cancer: Mechanisms of Tumor Hypoxia and Therapeutic Targeting

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.